β-Adrenergic blockade in patients with dementia and hip fracture is associated with decreased postoperative mortality

Ioannis Ioannidis1,2 · Ahmad Mohammad Ismail1,2 · Maximilian Peter Forssten1,2 · Yang Cao3 · Gary Alan Bass2,4 · Tomas Borg1,2 · Shahin Mohseni2,5

Abstract
Purpose Dementia, present in 20% of hip fracture patients, is associated with an almost threefold increase in postoperative mortality risk. These patients have a substantially higher incidence of cardiovascular, respiratory, and cerebrovascular mortality after hip fracture surgery compared to patients without dementia. This study aimed to investigate the association between beta-blocker therapy and postoperative mortality in patients with dementia undergoing hip fracture surgery.

Methods This nationwide study included all patients in Sweden with the diagnosis of dementia who underwent emergency surgery for a hip fracture between January 2008 and December 2017. Cases where the hip fracture was pathological or conservatively managed were not included. Poisson regression analysis with robust standard errors was performed while controlling for confounders to determine the relationship between beta-blocker therapy and all-cause, as well as cause-specific, postoperative mortality.

Results A total of 26,549 patients met the study inclusion criteria, of whom 8258 (31%) had ongoing beta-blocker therapy at time of admission. After adjusting for clinically relevant variables, the incidence of postoperative mortality in patients receiving beta-blocker therapy was decreased by 50% at 30 days [adj. IRR (95% CI) 0.50 (0.45–0.54), p < 0.001] and 34% at 90 days [adj. IRR (95% CI) 0.66 (0.62–0.70), p < 0.001]. Cause-specific mortality analysis demonstrated a significant reduction in the incidence of postoperative cardiovascular, respiratory, and cerebrovascular death within 30 and 90 days postoperatively.

Conclusion Beta-blocker therapy is associated with decreased postoperative mortality in hip fracture patients with dementia up to 90 days after surgery. This finding warrants further investigation.

Keywords Hip fracture · Dementia · Beta-blocker · β-Adrenergic blockade · Mortality
Background

Despite interventions and guidelines introduced during the past decade to reduce mortality, postoperative mortality has remained a constant challenge in managing hip fracture patients [1]. Furthermore, approximately 20% of hip fracture patients have dementia, a condition independently associated with an almost threefold increase in postoperative mortality risk [2–6]. These patients have a substantially higher incidence of cardiovascular, respiratory, and cerebrovascular mortality after hip fracture surgery compared to patients without dementia [7]. The hyper-adrenergic state that follows a traumatic injury and subsequent surgery plays a role in these adverse outcomes [2, 8–12]. Beta-adrenergic blockade may reduce this hyper-adrenergic state and mitigate its toxic effect [11–14], in turn reducing mortality after traumatic injuries [2, 8, 9, 15]. Several previous studies have demonstrated a positive association between beta-blocker therapy (BB) and a reduction in postoperative mortality after non-cardiac surgery, including in patients with isolated hip fractures [2, 9, 10, 16]. This study investigates the association between beta-blocker therapy and postoperative mortality in patients with dementia undergoing hip fracture surgery, with the hypothesis that beta-blocker therapy is associated with decreased mortality.

Methods

The Swedish National Ethical Review Authority approved the current study (reference 2020-04161), which adhered to the Declaration of Helsinki principles and the STROBE guidelines [17]. Rikshöft, the prospective Swedish national hip fracture quality registry, was used as the basis for the current study [18]. The date of hospital admission, age, sex, fracture type, American Society of Anesthesiologist (ASA) classification, surgical method, date of surgery, and hospital discharge date were retrieved from Rikshöft. Patients’ social security numbers were then used to cross-reference the data from Rikshöft with the time of death and comorbidity data from the Swedish National Board of Health and Welfare quality registers. An age-adjusted Charlson Comorbidity Index (CCI) was calculated from the comorbidity data [19]. All patients diagnosed with dementia who underwent primary emergency surgery for a hip fracture between January 1, 2008, and December 31, 2017 were included in the current study. Cases where the hip fractures were pathological, i.e. non-traumatic, or conservatively managed, were not included.

Beta-blocker use

We further cross-referenced the Rikshöft database with the Swedish National Board of Health and Welfare Prescribed Drug Registry, a population-based database containing all prescriptions issued in Sweden, to link beta-blocker prescriptions to individual hip fracture patients. Beta-blocker use was defined as patients who filled a prescription for any beta-blocker (ACT codes C07AA, C07AB, and C07AG) within 12 months before the date of surgery. We selected 12 months since beta-blockers are rarely discontinued once prescribed and are commonly issued on a long-term basis, with a single prescription spanning up to 12 months. Information regarding dose and generic drug names was also collected from this database. According to national guidelines set by the Swedish Society of Anesthesiology and Intensive Care, ongoing beta-blocker therapy should not be discontinued before surgery in the absence of absolute contraindications.

Statistical analysis

The cases were divided into two cohorts: ongoing beta-blocker therapy (BB+) and no beta-blocker therapy (BB−). Patient demographics and clinical characteristics were compared between the cohorts. Categorical variables were reported with percentages, while continuous variables were reported as a mean and standard deviation (SD) or median and interquartile range (IQR). Pearson’s Chi-squared test and Fisher’s exact test were used to determine the statistical significance of differences between categorical variables. The Student’s t test was used for the normally distributed variable, age. Length of stay was not normally distributed; hence, the Mann–Whitney U test was applied. The primary outcome of interest was 30-day postoperative all-cause and cause-specific mortality. The secondary outcome of interest was 90-day postoperative all-cause and cause-specific mortality.

A Poisson regression model was employed to investigate the association between beta-blocker therapy and 30-day and 90-day postoperative mortality. Analyses were performed while adjusting for age, sex, time to surgery, ASA classification, fracture type, type of surgery, prior myocardial infarctions, prior cerebrovascular events, peripheral vascular disease, chronic obstructive pulmonary disease, congestive heart failure, connective tissue diseases, diabetes mellitus, liver disease, chronic kidney disease, as well as local tumors and metastatic carcinoma. The analyses were repeated with 30- and 90-day cause-specific mortalities. Results are reported as incidence rate ratios (IRR) with 95% confidence intervals (CI). Statistical
β-Adrenergic blockade in patients with dementia and hip fracture is associated with decreased

Discussion

The association between beta-blocker therapy and postoperative mortality in patients with dementia and hip fractures has not been previously described. Poisson regression analysis demonstrated an association between patients with ongoing beta-blocker therapy and a reduction in postoperative mortality after both 30 and 90 days. Postoperative mortality resulting from cardiovascular, pulmonary, and cerebrovascular events was also significantly reduced in patients with ongoing beta-blocker therapy.

Despite interventions and guidelines aimed at improving perioperative care after hip fracture surgery, postoperative mortality remains high [1]. The majority of these deaths are due to cardiovascular or other causes not attributable to the surgical procedure’s technical aspects. The aggregation of comorbidities and aging into overall frailty may exacerbate the physiological stress response induced by the trauma, surgical procedure, and postoperative rehabilitation [1, 8, 21–23]. It has previously been postulated that the posttraumatic hyper-adrenergic state can be reduced with beta-blockers, thereby potentially reducing the mortality rate among patients who have experienced physical trauma [2, 8–12]. This association has been found in several studies conducted on trauma patients, major non-cardiac surgical procedures, such as elective abdominal colorectal cancer resections, emergency laparotomy to geriatric patients, and more recently in hip fracture patients [2, 9, 15, 24]. Ahl and colleagues reviewed 134,915 hip fracture cases, demonstrating a 72% reduction in the incidence of 30-day all-cause postoperative mortality in patients with ongoing beta-blocker therapy [adj. IRR (95% CI) 0.28 (0.26–0.29), p < 0.001] [2]. In the current study population, which only contains hip fracture patients diagnosed with dementia, beta-blocker therapy was associated with a 50% reduction in 30-day postoperative mortality.

Approximately 20% of the hip fracture patients have dementia, which has been strongly linked to worse outcomes [2–6], with a significantly higher risk of cardiovascular, respiratory, and cerebrovascular mortality after hip fracture surgery compared to patients without dementia [7]. In the last 15 years, two meta-analyses and a Cochrane
review have been published on beta-blocker therapy and non-cardiac surgery, outlining its cardioprotective effects [25–27]. Consequently, international guidelines from the American Heart Association, American College of Cardiology (AHA/ACC), and the European Society of Cardiology (ESC) warn against discontinuing regular beta-blockers before or following any surgery. Expert consensus further recommends beta-blocker initiation in intermediate to high-risk patients [≥ 2 clinical risk factors, ASA class ≥ 3, and over three factors from the Revised Cardiac Risk Index (RCRI)] [28, 29]. Many hip fracture patients with dementia fall in the high-risk patient category and should be considered for preoperative beta-blocker initiation. In the current study population, over 65% of beta-blocker naive patients had an ASA class ≥ 3, a CCI score over 5, and multiple risk factors from the RCRI. These patients could potentially have benefited from perioperative beta-blocker therapy.

| Table 1 Patient demographics and clinical characteristics in patients with dementia undergoing hip fracture surgery, with and without beta-blocker therapy |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Age in years, mean [SD] | BB − N=18,291 | BB + N=8258 | p value | | |
| Sex, n (%) | 85 [7] | 85 [7] | 0.019 | | |
| Female | 12,500 (68.3) | 5869 (71.1) | | | |
| Male | 5791 (31.7) | 2389 (28.9) | | | |
| Type of beta-blocker, n (%) | | | | N/A | |
| Metoprolol | – | 5013 (60.7%) | | | |
| Bisoprolol | – | 1505 (18.2%) | | | |
| Atenolol | – | 1009 (12.2%) | | | |
| Other | – | 731 (8.9%) | | | |
| Time to surgery, n (%) | | | <0.001 | | |
| < 24 h | 12,470 (68.2) | 5319 (64.4) | | | |
| > 24 h | 5821 (31.8) | 2939 (35.6) | | | |
| ASA classification, n (%) | | | <0.001 | | |
| 1 | 239 (1.3) | 44 (0.5) | | | |
| 2 | 5300 (29.0) | 1534 (18.6) | | | |
| 3 | 10,826 (59.2) | 5492 (66.5) | | | |
| 4 | 1567 (8.6) | 1000 (12.1) | | | |
| 5 | 27 (0.1) | 11 (0.1) | | | |
| Missing | 332 (1.8) | 177 (2.1) | | | |
| Charlson Comorbidity Index, n (%) | | | <0.001 | | |
| ≤ 4 | 2062 (11.3) | 436 (5.3) | | | |
| 5–6 | 11,889 (65.0) | 4537 (54.9) | | | |
| ≥ 7 | 4340 (23.7) | 3285 (39.8) | | | |
| Fracture type, n (%) | | | <0.001 | | |
| Non-displaced cervical (garden 1–2) | 2551 (13.9) | 989 (12.0) | | | |
| Displaced cervical (garden 3–4) | 7004 (38.3) | 3104 (37.6) | | | |
| Basicervical | 623 (3.4) | 286 (3.5) | | | |
| Pertrochanteric (two fragments) | 3360 (18.4) | 1527 (18.5) | | | |
| Pertrochanteric (multiple fragments) | 3513 (19.2) | 1696 (20.5) | | | |
| Subtrochanteric | 1235 (6.8) | 653 (7.9) | | | |
| Missing | 5 (0.0) | 3 (0.0) | | | |
| Type of surgery, n (%) | | | <0.001 | | |
| Pins or screws | 3305 (18.1) | 1385 (16.8) | | | |
| Screws or pins with sideplate | 4512 (24.7) | 1949 (23.6) | | | |
| Intramedullary rod | 4262 (23.3) | 2211 (26.8) | | | |
| Hemiarthroplasty | 5839 (31.9) | 2532 (30.7) | | | |
| Total hip replacement | 365 (2.0) | 179 (2.2) | | | |
| Missing | 8 (0.0) | 2 (0.0) | | | |

BB − no beta-blocker therapy; BB + ongoing beta-blocker therapy; SD standard deviation; ASA American Society of Anesthesiologists
β-Adrenergic blockade in patients with dementia and hip fracture is associated with decreased...

Perioperative myocardial infarction is associated with a fivefold increase in mortality. Thirty-four percent of all deaths within 90 days of the operation followed significant cardiac events, making it the most common cause of death in our study. Its incidence (per 1000 surgeries) increases from 0.064 in low-risk patients to 15.8% among higher-risk patients (ASA Class ≥ 3, age ≥ 80 years, high-risk surgery) [30]. The current study population, which is drawn from a national patient population, is both older (with a mean age of 85) and often has an ASA classification ≥ 3; accordingly, they have a high risk for postoperative myocardial infarction. Despite their more advanced age, greater comorbidity burden (including cardiovascular comorbidities), and higher preoperative ASA classifications, the BB+ cohort had lower crude mortality rates both 30 and 90 days postoperatively. Furthermore, the adjusted 30- and 90-day postoperative cardiovascular mortality risk was reduced by 52% and 36%, respectively, in the BB+ cohort compared to the BB− cohort. This finding makes beta-blockers, which are both readily available, cheap, and have a well-known side-effect profile, very appealing for use in clinical practice.

The retrospective nature of this study restricts the analyses to available variables, prohibiting conclusions about

| Table 2 | Preoperative comorbidities in patients with dementia undergoing hip fracture surgery, with and without beta-blocker therapy |
|----------------|----------------|----------------|
|               | BB− N=18,291 | BB+ N=8258 |
| Hypertension, n (%) | 5624 (30.7) | 4617 (55.9) | < 0.001 |
| Arrhythmia, n (%) | 2194 (12.0) | 2955 (35.8) | < 0.001 |
| Myocardial infarction, n (%) | 653 (3.6) | 907 (11.0) | < 0.001 |
| Heart failure, n (%) | 2116 (11.6) | 2363 (28.6) | < 0.001 |
| Peripheral vascular disease, n (%) | 495 (2.7) | 431 (5.2) | < 0.001 |
| Cerebrovascular event, n (%) | 3521 (19.2) | 2250 (27.2) | < 0.001 |
| Chronic obstructive pulmonary disease, n (%) | 1684 (9.2) | 988 (12.0) | < 0.001 |
| Connective tissue disease, n (%) | 654 (3.6) | 391 (4.7) | < 0.001 |
| Peptic ulcer disease, n (%) | 565 (3.1) | 342 (4.1) | < 0.001 |
| Liver disease, n (%) | 94 (0.5) | 89 (1.1) | < 0.001 |
| Diabetes Mellitus, n (%) | 2126 (11.6) | 1632 (19.8) | < 0.001 |
| Hemiplegia, n (%) | 256 (1.4) | 206 (2.5) | < 0.001 |
| Chronic kidney disease, n (%) | 678 (3.7) | 632 (7.7) | < 0.001 |
| Local tumor, n (%) | 1741 (9.5) | 870 (10.5) | 0.011 |
| Metastatic carcinoma, n (%) | 262 (1.4) | 104 (1.3) | 0.290 |

| Table 3 | Crude outcomes in patients with dementia undergoing hip fracture surgery, with and without beta-blocker therapy |
|----------------|----------------|----------------|
|               | BB− N=18,291 | BB+ N=8258 |
| Hospital length of stay, days | < 0.001 |
| Median [IQR] | 6 [4, 10] | 7 [5, 11] |
| Missing | 163 (0.9) | 62 (0.8) |
| 30-day mortality, n (%) | 2655 (14.5) | 765 (9.3) | < 0.001 |
| 90-day mortality, n (%) | 4384 (24.0) | 1528 (18.5) | < 0.001 |

| Table 4 | Cause of mortality in patients with dementia undergoing hip fracture surgery, with and without beta-blocker therapy |
|----------------|----------------|----------------|
|               | BB− N=18,291 | BB+ N=8258 |
| Cardiovascular | 950 (5.2%) | 306 (3.7%) | < 0.001 |
| Respiratory | 502 (2.7%) | 104 (1.3%) | < 0.001 |
| Cerebrovascular | 86 (0.5%) | 19 (0.2%) | 0.005 |
| Sepsis | 57 (0.3%) | 14 (0.2%) | 0.052 |
| MODS | 882 (4.8%) | 260 (3.1%) | < 0.001 |
| Unknown | 162 (0.9%) | 55 (0.7%) | 0.077 |

| Cause of mortality | 30-day mortality | 30-day mortality | p value | 90-day mortality | 90-day mortality | p value |
|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Cardiovascular | 950 (5.2%) | 306 (3.7%) | < 0.001 | 1443 (7.9%) | 583 (7.1%) | 0.020 |
| Respiratory | 502 (2.7%) | 104 (1.3%) | < 0.001 | 683 (3.7%) | 165 (2.0%) | < 0.001 |
| Cerebrovascular | 86 (0.5%) | 19 (0.2%) | 0.005 | 263 (1.4%) | 54 (0.7%) | < 0.001 |
| Sepsis | 57 (0.3%) | 14 (0.2%) | 0.052 | 107 (0.6%) | 35 (0.4%) | 0.120 |
| MODS | 882 (4.8%) | 260 (3.1%) | < 0.001 | 1,481 (8.1%) | 536 (6.5%) | < 0.001 |
| Unknown | 162 (0.9%) | 55 (0.7%) | 0.077 | 382 (2.1%) | 144 (1.7%) | 0.069 |

BB− no beta-blocker therapy; BB+ ongoing beta-blocker therapy; IQR interquartile range

Perioperative myocardial infarction is associated with a fivefold increase in mortality. Thirty-four percent of all deaths within 90 days of the operation followed significant cardiac events, making it the most common cause of death in our study. Its incidence (per 1000 surgeries) increases from 0.064 in low-risk patients to 15.8% among higher-risk patients (ASA Class ≥ 3, age ≥ 80 years, high-risk surgery) [30]. The current study population, which is drawn from a national patient population, is both older (with a mean age of 85) and often has an ASA classification ≥ 3; accordingly, they have a high risk for postoperative myocardial infarction. Despite their more advanced age, greater comorbidity burden (including cardiovascular comorbidities), and higher preoperative ASA classifications, the BB+ cohort had lower crude mortality rates both 30 and 90 days postoperatively. Furthermore, the adjusted 30- and 90-day postoperative cardiovascular mortality risk was reduced by 52% and 36%, respectively, in the BB+ cohort compared to the BB− cohort. This finding makes beta-blockers, which are both readily available, cheap, and have a well-known side-effect profile, very appealing for use in clinical practice.

The retrospective nature of this study restricts the analyses to available variables, prohibiting conclusions about
causality. One limitation was the coding of dementia as a single diagnosis in the dataset; the authors recognize that dementia describes a spectrum of conditions with a large degree of heterogeneity in their pathophysiology and mortality rates. The severity of dementia and preoperative functional status of each patient was also unknown. Regarding beta-blocker therapy, we used the prescription data to make reasonable assumptions about which patients were receiving ongoing beta-blocker therapy at the time of surgery. However, we could neither be confident of full compliance with treatment nor eliminate the risk that there was a discontinuation of therapy within that period. However, the authors believe discontinuation for such therapy to be highly unlikely since this is against the guidelines [28, 29]. Further, a previous study from our institution, including 2443 consecutive hip fracture cases, did not find a single case of beta-blocker therapy being discontinued [8].

The current study also demonstrates several strengths. The Rikshöft national database provides one of the largest sample populations to date studying postoperative mortality in hip fracture patients with dementia. Additionally, the universal healthcare system available in Sweden aids in the reduction of socioeconomic disparities in healthcare outcomes [31]. This is particularly important in patients with dementia since their condition inherently places them at a socioeconomic disadvantage [32].

### Conclusion

Beta-blocker therapy is associated with decreased postoperative mortality in hip fracture patients with dementia up to 90 days. This treatment could abrogate the high risk of postoperative mortality in this vulnerable patient population and should be further investigated, preferably in a pragmatic prospective randomized controlled trial.

### Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s00068-021-01723-y.

### Funding

Open access funding provided by Örebro University. The authors received no funding for this work. Support was provided solely from departmental sources.

### Data availability

May be made available on reasonable request provided the appropriate ethical approval is sought and approved.

### Declarations

#### Conflict of interest

The authors have no conflicts of interest to disclose.

#### Ethical approval

The Swedish National Ethical Review Authority approved the current study (reference 2020–04161).

#### Consent to participate

Due to the retrospective nature of this study no further consent were sought.

#### Consent to publish

Due to the retrospective nature of this study no further consent were sought.

### Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain

| Variable                  | 30-day IRR (95% CI)     | p value | 90-day IRR (95% CI)    | p value |
|---------------------------|-------------------------|---------|------------------------|---------|
| All-cause mortality       |                         |         |                        |         |
| BB –                      | ref                     | < 0.001 | ref                    | < 0.001 |
| BB +                      | 0.50 (0.45–0.54)        |         | 0.66 (0.62–0.70)       |         |
| Cause-specific mortality  |                         |         |                        |         |
| Cardiovascular            | 0.48 (0.41–0.56)        | < 0.001 | 0.64 (0.57–0.72)       | < 0.001 |
| Respiratory               | 0.35 (0.27–0.46)        | < 0.001 | 0.43 (0.35–0.54)       | < 0.001 |
| Cerebrovascular           | 0.52 (0.27–0.98)        |         | 0.51 (0.36–0.73)       | < 0.001 |
| Sepsis                    | 0.44 (0.20–0.97)        |         | 0.68 (0.41–1.14)       | 0.142   |
| MODS                      | 0.56 (0.47–0.65)        | < 0.001 | 0.73 (0.65–0.82)       | < 0.001 |
| Unknown                   | 0.73 (0.49–1.07)        |         | 0.89 (0.71–1.11)       | 0.304   |

Poisson regression models with robust standard errors. Multiple imputations with chained equations were used to manage missing values. The model is adjusted for age, sex, time to surgery, ASA classification, fracture type, type of surgery, prior myocardial infarctions, prior cerebrovascular events, peripheral vascular disease, chronic obstructive pulmonary disease, congestive heart failure, connective tissue diseases, diabetes mellitus, liver disease, chronic kidney disease, as well as local tumors and metastatic carcinoma.

IRR incidence rate ratio; CI confidence interval; BB – no beta-blocker therapy; BB + ongoing beta-blocker therapy, MODS multi-organ dysfunction syndrome.
β-Adrenergic blockade in patients with dementia and hip fracture is associated with decreased…

References

1. Gundel O, Thygesen LC, Gögenur I, Ekloef S. Postoperative mortality after a hip fracture over a 15-year period in Denmark: a national register study. Acta Orthop. 2020;91(1):58.

2. Ahl R, Mohammad Ismail A, Borg T, Sjölin G, Forsten MP, Cao Y, et al. A nationwide observational cohort study of the relationship between beta-blockade and survival after hip fracture surgery. Eur J Trauma Emerg Surg. 2021. https://doi.org/10.1007/s00068-020-01588-7.

3. Bai J, Zhang P, Liang X, Wu Z, Wang J, Liang Y. Association between dementia and mortality in the elderly patients undergoing hip fracture surgery: a meta-analysis. J Orthop Surg Res [Internet]. 2018 Nov 23 [cited 2020 Sep 11];13. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260652/.

4. Chiu H-C, Chen C-M, Su T-Y, Chen C-H, Hsieh H-M, Hsieh C-P, et al. Dementia predicted one-year mortality for patients with first hip fracture. Bone Jt. 2018;100(B(9)):1220–6.

5. Dutkiewicz R, Zetterberg H, Andreasson U, Blennow K, Nellgård B. Dementia and CSF-biomarkers for Alzheimer’s disease predict mortality after acute hip fracture. Acta Anaesthesiol Scand. 2020;64(1):93–103.

6. Clague JE, Craddock E, Andrew G, Horan MA, Pendleton N. Predictors of outcome following hip fracture. Admission time predicts length of stay and in-hospital mortality. Injury. 2002;33(1):1–6.

7. Ioannidis I, Mohammad Ismail A, Forssten MP, Ahl R, Cao Y, Borg T, et al. The mortality burden in patients with hip fractures and dementia. Eur J Trauma Emerg Surg. 2021. https://doi.org/10.1007/s00068-021-01612-4.

8. Mohammad Ismail A, Borg T, Sjölin G, Pourlotfi A, Holm S, Cao Y, et al. β-adrenergic blockade is associated with a reduced risk of 90-day mortality after surgery for hip fractures. Trauma Surg Acute Care Open [Internet]. 2020 Jul 29 [cited 2020 Sep 21];5(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394016/.

9. Ahl R, Matthiessen P, Sjölin G, Cao Y, Wallin G, Ljungqvist O, et al. Effects of beta-blocker therapy on mortality after elective colon cancer surgery: a Swedish nationwide cohort study. BMJ Open. 2020;10(7):e036164.

10. Ahl R, Matthiessen P, Cao Y, Sjölin G, Ljungqvist O, Mohseni S. The relationship between severe complications, beta-blocker therapy and long-term survival following emergency surgery for colon cancer. World J Surg. 2019;43(10):2527–35.

11. Loftus TJ, Efron PA, Moldawer LL, Mohr AM. β-Blockade use for traumatic injuries and immunomodulation: a review of proposed mechanisms and clinical evidence. Shock. 2016;46(4):341–51.

12. Friese RS, Barber R, McBride D, Bender J, Gentilello LM. Could beta blockade improve outcome after injury by modulating inflammatory profiles? J Trauma. 2008;64(4):1061–8.

13. Desborough JP. The stress response to trauma and surgery. Br J Anaesth. 2000;85(1):109–17.

14. Moor D, Aggarwal G, Quiney N. Systemic response to surgery. Surg Infect (Larchmt). 2017;15(3):220–3.

15. Maghami S, Cao Y, Ahl R, Dettlofsson E, Matthiessen P, Sarani B, et al. Beta-blocker therapy is associated with decreased 1-year mortality after emergency laparotomy in geriatric patients. Scand J Surg. 2019;108:464–70.

16. Nan Y, Jia F, Du X, Mei Z. Beta-blocker exposure for short-term outcomes following non-cardiac surgery: a meta-analysis of observational studies. Int J Surg. 2020;76:153–62.

17. WMA - The World Medical Association-WMA Declaration of Helsinki—ethical principles for medical research involving human subjects [Internet]. [cited 2020 May 13]. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/.

18. Om Rikshöft—RIKSHÖFT [Internet]. [cited 2021 Apr 20]. Available from: https://www.xn--rikshoft-e1a.se/om-oss.

19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.

20. R Development Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2008. Available from: http://www.R-project.org/.

21. Forsten MP, Mohammad Ismail A, Sjölin G, Ahl R, Wretenberg P, Borg T, et al. The association between the Revised Cardiac Risk Index and short-term mortality after hip fracture surgery. Eur J Trauma Emerg Surg. 2020. https://doi.org/10.1007/s00068-020-01488-w.

22. Cher EWL, Allen JC, Howe TS, Koh JSB. Comorbidity as the dominant predictor of mortality after hip fracture surgeries. Osteoporos Int. 2019;30(12):2477–83.

23. Choi HG, Lee YB, Rhyu SH, Kwon BC, Lee JK. Mortality and cause of death postoperatively in patients with a hip fracture: a national cohort longitudinal follow-up study. Bone Jt. 2018;100(B(4)):436–42.

24. Ahl R, Matthiessen P, Fang X, Cao Y, Sjölin G, Lindgren R, et al. β-Blockade in rectal cancer surgery: a simple measure of improving outcomes. Ann Surg. 2020;271(1):140–6.

25. Blessberger H, Kammler J, Domanovits H, Schlager O, Wildner B, Azar D, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity. The Cochrane Database of Systematic Reviews [Internet]. 2018 Mar [cited 2020 Sep 21];2018(3). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC649407/.

26. Devereaux PJ, Goldman L, Cook DJ, Gilbert K, Leslie K, Guyatt GH. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ. 2005;173(6):627–34.

27. Bangalore S, Witterslev J, Praneshe S, Sawhney S, Gluud C, Messerli FH. Perioperative β blockers in patients having non-cardiac surgery: a meta-analysis. Lancet. 2008;372(9654):1962–76.

28. Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College Of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;64(22):c77–137.

29. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al. Expert consensus document on β-adrenergic receptor blockers: the task force on beta-blockers of the European Society of Cardiology. Eur Heart J. 2004;25(15):1341–62.

30. Hallqvist L, Granath F, Bell M. Myocardial infarction after non-cardiac surgery: a national cohort longitudinal follow-up study. Bone Jt J. 2018;100(B(4)):436–42.

31. Veugelers PJ, Arvold NJ, Schmidt JA, Bozkurt B, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College Of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;64(22):c77–137.

32. Kivimäki M, Batty GD, Pentti J, Shipley MJ, Sipilä PN, Nyberg L. Cardiovascular disease and long-term survival following emergency surgery for colon cancer surgery: a Swedish nationwide cohort study. BMJ Open. 2020;10(7):e038164.

33. Blessberger H, Kammler J, Domanovits H, Schlager O, Wildner B, Azar D, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity. The Cochrane Database of Systematic Reviews [Internet]. 2018 Mar [cited 2020 Sep 21];2018(3). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC649407/.